Tetraphase Presents New Clinical and Preclinical Data for Novel AntibioticTP-434 at 2010 ICAAC
Data Shows TP-434 Has Potential as First-line, Broad-spectrum Antibiotic for Treatment of Gram-negative and Multidrug-resistant Infections
Additional Data Shows TP-434 as an Orally Effective Antibiotic
WATERTOWN, Mass.--(BUSINESS WIRE)--Sep 13, 2010 - Tetraphase Pharmaceuticals, Inc., yesterday presented new clinical and preclinical data for its lead drug candidate, TP-434, which demonstrated the novel antibiotic as a once-daily intravenous (I.V.) monotherapy capable of treating multidrug-resistant gram-negative pathogens while also having potency and broad spectrum coverage of other serious and multidrug-resistant gram-positive pathogens. Additionally, Tetraphase presented new data that showed the potential for TP-434 to be effective in an oral formulation, which makes TP-434 ideally suited as a first-line IV antibiotic with oral step-down for severe and life-threatening bacterial infections. These data were presented in an oral session and in two poster sessions at the 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston, MA, being held September 12-15. Tetraphase is a clinical stage biopharmaceutical company utilizing breakthrough synthetic chemistry technology to discover and develop next-generation antibiotics.
In the Poster Summary Session on “Novel Antimicrobial Agents and Strategies” on Sunday, September 12, Tetraphase reviewed key data relating to TP-434, highlighting Phase I clinical data that shows TP-434 was safe and well-tolerated with once-daily I.V. dosing, and preclinical data demonstrating TP-434's potency and efficacy against a broad range of multidrug-resistant and gram-negative pathogens. The main conclusions included:
“While there are other novel approaches in development that also address gram-negative pathogens, the data on TP-434 stand out because they reveal TP-434 to have a very broad spectrum, including difficult-to-treat pathogens and drug-resistant superbugs,” said Guy Macdonald, President and Chief Executive Officer of Tetraphase. “TP-434's unprecedented bacterial spectrum, combined with successful early clinical data positions TP-434 as a potential first-line therapy for severe and life-threatening bacterial infections.”
“Our plans include additional development of the oral formulation of TP-434 as a follow-on product opportunity to our TP-434 I.V. program, which would offer a unique advantage in the antibiotics market where there are few oral antibiotics capable of addressing multidrug-resistant bacterial infections,” added Mr. Macdonald.
In the Sunday poster presentations “Phase I Single and Multiple Ascending Dose Study of a Broad-Spectrum Fluorocycline, TP-434” and “Population Pharmacokinetic Modeling of TP-434, a Novel Fluorocycline, Following Single and Multiple Dose Administration,” the data showed the potential utility of TP-434 given as once-daily IV doses in the treatment of severe bacterial infections caused by multidrug-resistant gram-negative pathogens. By population pharmacokinetic analyses, TP-434 is expected to have utility at dose regimens up to and including 2 mg/kg/day.
TP-434, the lead product candidate in Tetraphase's clinical pipeline, is a potent new antibiotic effective against multidrug-resistant gram-negative pathogens. TP-434 is also effective against the broadest spectrum of other difficult-to-treat and multidrug-resistant pathogens, including multidrug-resistant gram-positive, anaerobic, and atypical species. TP-434's spectrum and pharmacokinetic properties are consistent with its use as once-daily monotherapy. Preliminary Phase 1 data have shown that TP-434 also has the potential to be developed as an oral therapy. TP-434 I.V. has successfully completed Phase 1 clinical studies and is poised to enter Phase 2 in 2010.
Tetraphase Pharmaceuticals is a clinical stage biopharmaceutical company utilizing its breakthrough synthetic chemistry technology platform to discover and develop next-generation tetracycline antibiotics that address unmet needs for serious infections such as drug resistance and gram-negative infections. The company has developed an emerging pipeline of potent novel antibiotics that provide a portfolio of intravenous and oral drug candidates with the potential to treat a wide range of infections, including broad-spectrum and selective-spectrum infections. To learn more about Tetraphase, please visit www.tphase.com.
Contact: Tetraphase Pharmaceuticals
David Lubner, 617-715-3551
The Yates Network
Kathryn Morris, 845-635-9828
Posted: September 2010